Givinostat inhibits ERK1/2 kinase phosphorylation and also reduces the levels of two transcription factors often up-regulated in MPN patients: NF-E2 and C-MYB [163,164]. The gene discussed is MAPK3; the disease is myeloproliferative disorder.